CFF provided a series of clinical trial updates in February 2017. Click the trial title to get more details.

The following alert was distributed on 02/21/2017:

Arikace for Nontuberculous Mycobacteria (NTM)

Description: This study looked at the safety and effectiveness of liposomal amikacin for inhalation (Arikaceā„¢), in treating nontuberculous mycobacterial lung disease (NTM).

Age: 12 Years to 75 Years

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 0

Length of Participation: 12 weeks

ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT01315236

The following alerts were distributed on 02/02/2017:

Phase 2 study of inhaled nitric oxide in people with CF

Description: This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 35 to 85%

Number of Visits: 10

Length of Participation: 43 days

ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT02498535

Phase 2 study of oral glutathione in children with cystic fibrosis

Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug glutathione in children with cystic fibrosis.

Age: 24 Months to 10 Years

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 4

Length of Participation: 6 months

ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT03020719